Press Release: BioCision and Brooks Automation Announce Industry's First Portable Cryogenic Biospecimen Transport System with Integrated Real-Time Temperature Monitoring

Liquid nitrogen-based carrier enables safe and reliable handling of frozen specimens and therapeutics for the most advanced, gap-free cold-chain management

PHOENIX, Ariz., ISBER, May 6, 2015 - BioCision, LLC, a leader in advanced biomaterial sample handling and standardization tools, and Brooks Automation, a global provider of automated sample storage systems for compound management and biorepositories, today announced the launch of the CryoPod™ carrier, a jointly developed liquid nitrogen (LN2)-based system for the safe, reliable, and protected handling and transport of cryogenic biospecimens. The portable, data-logging carrier was unveiled today at the annual meeting of the International Society for Biological and Environmental Repositories (ISBER) in Phoenix, Arizona.

The result of a 12-month joint development project, the patent-pending CryoPod carrier is a breakthrough technology that enables more than 4 hours of less than -150°C temperature stability for cryogenically frozen biospecimens and therapeutics, keeping them below glass transition (Tg) temperature where biological activity may cease.

Researchers and clinicians often rely on improvised methods to handle and transport frozen biospecimens and therapies such as placing samples on dry ice, which is considerably warmer at a temperature of -78°C, handling heavy LN2 dry shippers that must be transported on a cart or dolly, or handling unabsorbed LN2 in open containers that present a safety issue. These methods can be hazardous for the operator, and often introduce temperature fluctuations that could impact the integrity of a frozen specimen or the efficacy of a valuable therapeutic.

The CryoPod carrier provides a safe, portable, and trackable solution for hand carrying temperature-sensitive cryogenically frozen biological materials through the use of a special material that holds and minimizes LN2 movement and prevents LN2 from coming in contact with the samples. The instrument displays temperature, date, and time; and features audible and visual alarms, plus logging capabilities. The carrier can integrate with an automated filling station that ensures hands-free, safer handling, and replenishing of the LN2 charge in less than 15 minutes.

“The CryoPod carrier offers biobanking customers a solution for safely transporting biospecimens between long-term storage and their labs and work benches," said Dusty Tenney, president of Brooks Life Science Systems. “Our strategic partnership with BioCision has enabled us to co-develop this cryogenic carrier, providing a safe and effective alternative for transporting biomaterials."

With the emergence of cell therapy and other live therapeutics, as well as the rapid global growth of biobanks and repositories, CryoPod technology addresses a critical gap in the cold chain of custody and aids in minimizing temperature fluctuations for frozen specimens, preserving biosample integrity.

“In our partnership with Brooks, we were able to come together to address a critical unmet need in handling important cryogenic specimens and ensure they are handled with utmost care for future use," said Hugh Douglas, COO of BioCision. “We continue to focus on sample handling standardization, and the CryoPod carrier is an important advancement in the way valuable specimens and therapeutics are safeguarded."

The CryoPod carrier is a lightweight, compact LN2-based carrier weighing less than 20 pounds. The handle enables easy one-hand carrying for transporting samples between labs and buildings or around metro areas. Both Brooks and BioCision will sell the CryoPod carrier directly and through established distribution channels when it is available later this year.

BioCision and Brooks are exhibiting at the 2015 ISBER annual meeting May 6-8, 2015 in Phoenix, Arizona. BioCision is exhibiting in booths 519 and 521, and Brooks in booths 313 and 412.

About Brooks Automation
Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, we have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; we have expanded our reach to meet the needs of customers in the life sciences industry, analytical & research markets, and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe, and Asia.

About BioCision, LLC
BioCision is a life science research and development company that develops products and solutions for process standardization throughout the healthcare industry. The intuitive design and interconnectivity of BioCision products enables researchers, clinicians and manufacturers to protect the integrity of temperature-sensitive therapeutics, biological samples, and biomaterials.  By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.
For more information visit, or visit the BioCision blog for news and expert insight at

Media Information

Marla Kertzman
209 852 9027

Brooks Automation
Barbara Culhane
Corporate Marketing Manager
978 262 2816

Tiziani Whitmyre, Inc.
Don Goncalves

Photos: Download a high-resolution image for publication.